Our findings may provide new insights regarding the mechanisms of estrogen- and antiestrogen-induced cell migration in endometrial cancer cells with low or without ERs, suggesting the possibility of anti-GPR30 as a potential therapeutic intervention for the treatment of human endometrial cancers. Here, GPER1 is linked to endometrial cancer.